|
|
|
|
|
|
|
|
|
THE RISE OF VIRTUAL CLINICAL TRIALS
COVID-19 has amplified the industry's need for virtual trial capabilities. Sponsors, CROs, and other members of the biopharmaceutical industry are adapting at a rapid pace. What can we expect as we enter this new era of clinical development?
Join a broad panel of industry experts for an interactive Trial Better Live briefing on the potential and limitations of trial virtualization. They’ll also cover:
The impact of virtual trials on patient consent
The continued role of disruptive innovation post-COVID
Insights from a recently-completed industry survey on the increased use of virtual trial capabilities
Join us on May 20 and add your voice to the discussion.
|
|
|
|
David B. Nash
Thomas Jefferson University
|
|
|
Jason Hwang
Jason Hwang LLC
|
|
|
Richard Etwaru
Hu-manity.co
|
|
|
|
Ken Faulkner, Ph.D.
ERT
|
|
|
Donna Reed
ERT
|
|
|
|
|
|
|
© 2020 ERT Clinical. All Rights Reserved.
ERT
1818 Market Street
Suite 1000
Philadelphia, PA 19103
|
|
|
Message above is a paid advertisement. Content is provided by the sponsor. You received this email because you are a customer of Applied Clinical Trials, an MJH Life Sciences™ brand. You are on the mailing list as %%emailaddress%%.
|
|
|
